Gasparetto, C., Lipe, B., Tuchman, S., Callander, N. S., Lentzsch, S., Baljevic, M., … Schiller, G. J. (2020). Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Gasparetto, Cristina, Brea Lipe, Sascha Tuchman, Natalie Scott Callander, Suzanne Lentzsch, Muhamed Baljevic, Adriana C. Rossi, et al. “Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Gasparetto C, Lipe B, Tuchman S, Callander NS, Lentzsch S, Baljevic M, et al. Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM). In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Gasparetto, Cristina, et al. “Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Gasparetto C, Lipe B, Tuchman S, Callander NS, Lentzsch S, Baljevic M, Rossi AC, Bahlis NJ, White D, Chen C, Sutherland HJ, Kotb R, LeBlanc R, Sebag M, Venner CP, Bensinger W, Sheehan H, Ju Y, Kai K, Schiller GJ. Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM). JOURNAL OF CLINICAL ONCOLOGY. 2020.